Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. Common Stock
Your view on COAG
Overview
What the company does, where it operates, and who runs it.
About Hemab Therapeutics Holdings, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Benny Sorensen
- Headquarters
- 101 Main Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Benny Sorensen
- Headquarters
- 101 Main Street, Cambridge, MA, US
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies.
The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency.
Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs.
Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Hemab Therapeutics Holdings, Inc. Common Stock, and the rating behind it. COAG last traded at $28.70; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Hemab Therapeutics Holdings, Inc. Common Stock. Starting points for Hemab Therapeutics Holdings, Inc. Common Stock: EPS -$1.56, beta 1.85 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Hemab Therapeutics Holdings, Inc. Common Stock. Hemab Therapeutics Holdings, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Hemab Therapeutics Holdings, Inc. Common Stock. Trailing twelve-month EPS for Hemab Therapeutics Holdings, Inc. Common Stock stands at -$1.56. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Hemab Therapeutics Holdings, Inc. Common Stock. Hemab Therapeutics Holdings, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Hemab Therapeutics Holdings, Inc. Common Stock valued side by side against its closest peers. Hemab Therapeutics Holdings, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Hemab Therapeutics Holdings, Inc. Common Stock, and how their positions are changing. At a $1.34B market value, institutional positions materially move Hemab Therapeutics Holdings, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Hemab Therapeutics Holdings, Inc. Common Stock executives and directors. Shares of Hemab Therapeutics Holdings, Inc. Common Stock have traded between $23.00 and $53.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Hemab Therapeutics Holdings, Inc. Common Stock. Hemab Therapeutics Holdings, Inc. Common Stock is a $1.34B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Hemab Therapeutics Holdings, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Hemab Therapeutics Holdings, Inc. Common Stock. Coverage tracks Hemab Therapeutics Holdings, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.